Status:
COMPLETED
A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Infections
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the safety of anti-HIV drugs combined with low-dose chemotherapy (consisting of cyclophosphamide \[CTX\]) in HIV-positive patients. This study examines whethe...
Detailed Description
HAART is a potent suppressor of plasma and lymph node HIV RNA. However, studies suggest that HAART cannot significantly diminish reservoirs of chronically HIV-infected cells. Strategies designed to er...
Eligibility Criteria
Inclusion Criteria
You may be eligible for this study if you:
- Are HIV-positive.
- Have a CD4 count above 300 cells/mm3 within 30 days of study entry.
- Have an HIV viral load between 10,000 and 200,000 copies/ml.
- Are between the ages of 18 and 50.
- Agree to practice abstinence or to use a barrier method of birth control during the study (such as condoms).
Exclusion Criteria
You may not be eligible for this study if you:
- Have had cancer requiring chemotherapy or radiotherapy or certain nervous system diseases.
- Are sensitive to E. coli-derived proteins.
- Have an active AIDS-defining illness.
- Require certain medications.
- Are pregnant or breast-feeding.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
October 1 2001
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00000899
End Date
October 1 2001
Last Update
October 29 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Univ of North Carolina
Chapel Hill, North Carolina, United States, 275997215
2
Duke Univ Med Ctr
Durham, North Carolina, United States, 27710